Starpharma Reports Positive Results From SARS-CoV-2 Antiviral Testing Of SPL7013

(RTTNews) - Starpharma announced that its VivaGel active, astodrimer sodium (SPL7013), has been shown in laboratory studies to have significant antiviral activity against the coronavirus that causes COVID-19. The SARS-CoV-2 antiviral testing of SPL7013 was conducted under contract by Melbourne-based 360Biolabs.

Starpharma said it is evaluating product concepts and formulation options for SPL7013, which may have potential applications in the prevention and management of COVID-19.

Jackie Fairley, Starpharma CEO, said: "We are now exploring a number of product opportunities, including a potential preventative application to reduce the risk of infection. Such a product could provide additional personal protection including for those in the frontline of this crisis, such as doctors, nurses and other essential workers."

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.